Management team

Lars Adlersson
Born in 1964. B.Sc. (Econ.). CEO and President. Employed since 2003. Previous appointments; Marketing VP, Marketing Director and CEO of GlaxoWellcome (Sweden) and CEO of GSK (Austria).
Number of Medivir shares: 3,200 class B.
Stock options* 2004 - 2009: 9,000
Stock options** 2005 - 2010: 15,000
Stock options 2007 – 2012 : 46,000

Börje Darpö
Born in 1952. Board certified in cardiology and internal medicine, VP Development. Head of Clinical Development since 2007. Previous leading positions within Clinical Pharmacology Pharmacia/Pfizer, Quintiles and Daiichi Medical Research UK/USA
Number of shares in Medivir: 8,900 class B.

Christina Kassberg
Born in 1968. BSc, Bachelor of Science in Business. Vice President, Business Control and Administration.
Employed since 2000. Previous employment includes Controller Medivir AB , responsible for finance and accounting, Skandia Link Multifond and auditor Öhrling Pricewaterhouse Coopers.
Number of Medivir shares: 8,406 class B (including family holdings)
Stock options* 2004 – 2009: 2,000
Stock options** 2005 – 2010: 2,000
Stock options 2007 – 2012: 20,000

Rein Piir
Born in 1958. B.Sc. (Econ.) Chief Financial
Officer/Vice President, Investor Relations.
Employed since 2000.
Previous employment includes senior positions in Healthcare & Research at securities institution D. Carnegie AB and Research & Strategy at SPP.
Number of Medivir shares: 0.
Stock options* 2004 - 2009: 4,800
Stock options** 2005 - 2010: 7,000
Stock options 2007 – 2012: 20,000

Bertil Samuelsson
Born in 1950. Ph.D., Professor. Vice President, Discovery Research. Employed since 1999.
Previous employment includes Head of Medicinal Chemistry, AstraZeneca, Mölndal, Sweden.
Number of shares in Medivir (including family
holdings): 32,100 class B.
Stock options* 2004 - 2009: 4,800
Stock options** 2005 - 2010: 7,500
Stock options 2007 – 2012: 22,000

Tom Schlossman
Born in 1964. Vice President, General Counsel. Employed since 2004.
Previous positions include legal counsel and
company lawyer at Astra, and assignments for several venture capital companies including HealthCap.
Number of shares in Medivir: 2,200 class B.
Stock options* 2004 - 2009: 6,800
Stock options** 2005 - 2010: 7,000
Stock options 2007 – 2012: 20,000

Paul Wallace
Born in 1962. Ph.D. University of Cambridge,
Vice President, Business Development.
Employed since 2000.
Previously Business Development Manager
at Peptide Therapeutics plc and Director of Research at Eclagen, both in the UK.
Number of Medivir shares: 0.
Stock options* 2004 - 2009: 4,800
Stock options** 2005 - 2010: 7,500
Stock options 2007 – 2012: 22,000

Stefan Mårtensson
Born in 1959. B.Sc. (Econ.).
Vice President, Sales & Marketing.
Employed since 2007.
Previous employment includes Commercial Director within Glaxo Wellcome/GSK and Nordic Business Unit Head and Head of Marketing within Novartis.
Number of shares in Medivir: 0.

* Outstanding options
Upon full subscription, the total number of outstanding detachable Warrants as of 31 December 2006, 676,995, confer rights to 695,695 new class B shares, corresponding to some 5.1% of the share capital and 3.7% of the vote upon full exercise. 0 (0) stock options were exercised in the year, converted to 0 (0) new class B shares. As of 1 January, the total number of outstanding detachable warrants was 886,995, and 676,995 at 31 December. The difference comprises the 210,000 expired warrants relating to the 2001-2006 plan.

** As above, apart from the first one-third not being exercisable until two years after the date of apportionment.